Please login to the form below

Not currently logged in
Email:
Password:

IQWiG

This page shows the latest IQWiG news and features for those working in and with pharma, biotech and healthcare.

Blind man's buff

Blind man's buff

In IQWIG’s words, ‘the rhetoric of novelty and innovation creates an assumption that new products are better than existing ones’. ... The IQWIG evidence tells us that our industry is wasteful of its innovative resources.

Latest news

More from news
Approximately 23 fully matching, plus 45 partially matching documents found.

Latest Intelligence

  • The gold standard of scientific evidence The gold standard of scientific evidence

    PBAC appraisals, 64% of NICE appraisals and all IQWiG appraisals relied on RCT-based evidence.

  • Digital disruption Digital disruption

    best patient outcomes - information that would probably come in very handy for submissions to the likes of NICE or IQWiG.

  • Stepping up to payer-driven market access Stepping up to payer-driven market access

    Combined with the demanding - and often less familiar - requirements of the GBA and IQWIG in Germany and other agencies in Europe, these changes make early understanding of the payer environment critical

  • The price is right? The price is right?

    IQWiG evaluations often focus on different patient populations from those used in the clinical trials. ... The dynamic between the G-BA and IQWiG makes pricing and reimbursement an extremely complex process.”.

  • Biosimilars - the same, but different? Biosimilars - the same, but different?

    After regulatory clarity, the focus will certainly move to health technology assessment bodies, such as Germany's IQWiG and the UK's NICE, if biosimilars' place in clinical practice is to ... For its part IQWiG has yet to assess any biosimilar products.

More from intelligence
Approximately 4 fully matching, plus 17 partially matching documents found.

Latest from PMHub

  • Oncology drugs under AMNOG

    Usually the G-BA also seeks the advice of expert Health Technology Assessment (HTA) body IQWiG (the Institute for Quality and Efficiency in Healthcare), to determine the level of added benefit ... The G-BA and IQWiG restricted these options to therapies

More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
TRIDUCIVE

Triducive are a strategic healthcare consultancy who produce communications that have practical, dynamic application that encourage behaviour change because of the...

Latest intelligence

How innovating study sites can improve patient recruitment efficiency
There are so many ways that clinical trials have innovated over the last few years. There is now a larger focus on making trials more patient-centric, more virtualised, and more...
PME-MAY21-Cover
Avoiding A Series of Unfortunate Events: launch lessons from lockdown
Chris Ross takes a novel look at launch excellence through the lens of COVID-19 and explores how pharma’s launch leaders are rewriting the story...
6 reasons patients drop out of clinical trials and 6 ways to fix it
If you’ve successfully recruited patients for your clinical trial, but one by one, they begin to drop out, then this information could be for you....